Deadline: 15-Jun-2026
The Japanese Headache Society, in partnership with Pfizer, is offering grants to support projects that improve migraine care through early diagnosis, appropriate treatment, and behavioral change. The initiative focuses on patient education, healthcare professional training, and workplace and school programs, aiming to strengthen coordination between specialists and non-specialists. Grants of up to 1.2 million JPY are available for projects running up to two years.
Overview of the Initiative
The Japanese Headache Society and Pfizer migraine care grant aims to enhance the quality of migraine management across Japan. The initiative encourages projects that promote early diagnosis, appropriate treatment, and behavioral change among patients and healthcare professionals. The program targets gaps in awareness, knowledge, and care delivery to ensure timely and effective migraine management.
Programme Focus Areas
Key focus areas include:
-
Encouraging patients who need treatment but have not sought medical consultation to change their behavior.
-
Facilitating cooperation between specialist and non-specialist doctors.
-
Promoting early diagnosis and appropriate treatment through dissemination of specialized knowledge.
-
Educating children and adolescents about migraine.
-
Training school physicians, occupational health professionals, public health nurses, and pharmacists to enhance understanding and awareness.
-
Developing and implementing headache education programs in workplaces and schools.
Expected Impact
Projects supported by this initiative are expected to:
-
Improve coordination among healthcare professionals managing migraine.
-
Increase early detection and timely treatment of migraine cases.
-
Enhance awareness and understanding of migraine among children, adolescents, and community healthcare providers.
-
Support the implementation of educational programs that integrate migraine awareness into schools and workplaces.
Who is Eligible
Eligible applicants include:
-
Medical, dental, nursing, allied health, and pharmacy professional schools
-
Healthcare institutions
-
Professional organizations and associations
-
Government agencies or entities focused on healthcare improvement
Applicants must be organizations, with the Project Lead or Principal Investigator employed or contracted by the applying entity. Individual applications are not accepted.
Funding and Duration
-
Maximum grant per project: 1.2 million JPY
-
Project duration: up to two years, from December 1, 2026, to November 30, 2028
Why It Matters
Migraines affect a significant portion of the population and are often underdiagnosed or undertreated. By promoting early identification, enhancing collaboration between healthcare providers, and increasing patient and community education, this initiative strengthens healthcare systems and improves outcomes for individuals living with migraine.
Common Tips and Mistakes to Avoid
Tips for Applicants: Focus on innovative interventions that change patient or professional behaviors, clearly outline collaboration strategies between specialists and non-specialists, and include measurable outcomes. Common Mistakes: Proposing projects outside the grant’s healthcare scope, targeting individual applicants instead of organizations, or lacking clear behavioral change or education strategies.
Frequently Asked Questions (FAQs)
1. Who can apply? Only organizations, including healthcare institutions, professional schools, professional associations, and government agencies.
2. What is the grant amount? Up to 1.2 million JPY per project.
3. What is the project duration? Up to two years, from December 1, 2026, to November 30, 2028.
4. Who must lead the project? The Project Lead or Principal Investigator must be employed or contracted by the applying organization.
5. What types of activities are supported? Patient education, healthcare professional training, school and workplace migraine awareness programs, and collaboration between specialists and non-specialists.
6. Are individual applicants eligible? No, only organizations can apply.
7. What is the expected impact? Improved migraine diagnosis and treatment, increased awareness, and better healthcare coordination.
Conclusion
The Japanese Headache Society and Pfizer grant strengthens migraine care in Japan by supporting projects that promote early diagnosis, behavioral change, and education across patient and professional communities. By funding interventions that improve healthcare coordination and awareness, the initiative contributes to better health outcomes and quality of life for individuals affected by migraine.
For more information, visit Pfizer.